Does Security Health Plan Cover Adderall?

Understanding Security Health Plan Formulary Tiers

Security Health Plan, a Wisconsin-based insurer affiliated with Marshfield Clinic Health System, organizes prescription drugs into tiered formularies that determine out-of-pocket costs. Generic mixed amphetamine salts (the chemical equivalent of Adderall) typically appear on Tier 2, which carries lower copayments than brand-name medications on Tier 3 or specialty tiers.

SHP operates multiple plan types, including HMO, POS, and Medicare Advantage products, each with its own formulary version. The FDA's Orange Book lists several therapeutically equivalent generic versions of amphetamine mixed salts in both immediate-release (IR) and extended-release (XR) formulations. When your prescriber writes for "Adderall," most pharmacies will automatically dispense the generic unless a "dispense as written" (DAW) code is specified. This substitution matters because it can reduce your copay by 50% or more.

For SHP members on commercial (employer-sponsored) plans, Tier 2 generics typically carry copays between $10 and $35 per 30-day fill. Brand-name Adderall, when covered at all, usually sits on Tier 3 with copays of $50 to $100. Some SHP Medicare Advantage plans place stimulants under additional utilization management, including quantity limits and refill-too-soon edits that prevent early fills [1]. The Centers for Medicare & Medicaid Services requires all Part D plans to cover at least two drugs per therapeutic class, and CNS stimulants fall under the "ADHD agents" class.

Formulary placement can change annually. SHP publishes updated formulary documents each January and mid-year if modifications occur. Always verify your specific plan's drug list through SHP's member portal or by calling the number on your insurance card.

Prior Authorization and Step-Therapy Requirements

SHP, like most commercial insurers, applies prior authorization (PA) to certain stimulant medications. Brand-name Adderall XR and newer amphetamine formulations (such as Mydayis) almost always require PA before the plan will pay.

Step therapy is common. SHP may require documented failure of or intolerance to methylphenidate (Ritalin, Concerta) before approving amphetamine-based treatments. The American Academy of Pediatrics (AAP) clinical practice guidelines note that both methylphenidate and amphetamine classes are considered first-line pharmacotherapy for ADHD, with no strong evidence favoring one class over the other as an initial choice [2]. A 2018 Lancet meta-analysis (N=19,510 across 133 trials) found amphetamines were the most efficacious ADHD medications in adults, while methylphenidate was most efficacious in children [3].

Your prescriber can initiate the PA process by submitting clinical documentation to SHP. Required documentation generally includes a confirmed ADHD diagnosis (using DSM-5 criteria), evidence of prior medication trials, and a rationale for the requested formulation. PA decisions typically arrive within 72 hours for standard requests and 24 hours for urgent requests. If denied, you have the right to appeal. The appeal must include a letter of medical necessity from your clinician. SHP processes first-level appeals within 30 days for commercial plans and 7 days for Medicare Advantage plans.

Generic vs. Brand-Name Adderall: What SHP Covers

The cost difference between generic and brand-name stimulants is significant, and SHP's formulary design strongly incentivizes generic use. Understanding this distinction can save hundreds of dollars annually.

Generic mixed amphetamine salts IR (immediate-release) tablets are manufactured by Teva Pharmaceuticals, Sandoz, Lannett, and others. The FDA requires bioequivalence testing for all approved generics, meaning they deliver the same active ingredient at the same rate and extent as the brand [4]. In practice, some patients report subjective differences between manufacturers. These reports have not been substantiated in controlled trials. A 2017 study published in the Journal of Clinical Pharmacology found no clinically meaningful pharmacokinetic differences between authorized generic and brand amphetamine mixed salts formulations [5].

For SHP members, generic IR tablets represent the lowest-cost option. Generic XR capsules cost more but still significantly less than brand Adderall XR, which Teva now markets after the original Shire patent expired. SHP's preferred drug list may specify particular generic manufacturers through its pharmacy benefit manager (PBM). If your pharmacy stocks a non-preferred generic, the copay could be slightly higher. Ask your pharmacist to confirm which manufacturer is on SHP's preferred list.

Brand-name Adderall IR has been largely discontinued from the U.S. market in favor of generics. Brand Adderall XR remains available but is rarely prescribed when identical generics exist. If your clinician believes the brand formulation is medically necessary (for example, due to documented adverse reactions to generic fillers or binders), SHP offers a formulary exception process. This requires a detailed letter from your prescriber explaining the clinical rationale.

How ADHD Diagnosis Affects Coverage Eligibility

SHP requires a documented ADHD diagnosis before covering stimulant medications. This is not unique to SHP. Most insurers gate stimulant coverage behind diagnostic confirmation due to the controlled-substance classification of amphetamines (Schedule II under the DEA).

The National Institute of Mental Health estimates that 4.4% of U.S. adults (ages 18 to 44) meet criteria for ADHD, though fewer than 20% of affected adults receive treatment [6]. Diagnosis in adults typically involves a clinical interview, symptom checklists (such as the Adult ADHD Self-Report Scale, or ASRS), and collateral history. SHP covers diagnostic evaluations performed by in-network psychiatrists, psychologists, and primary care physicians within the Marshfield Clinic network.

The DSM-5 requires at least five symptoms of inattention or hyperactivity-impulsivity present before age 12, persisting for six months or more, and causing functional impairment in two or more settings [7]. Some SHP plans require the initial ADHD evaluation to be conducted by a specialist (psychiatrist or neuropsychologist) rather than a general practitioner, particularly for adult-onset presentations. Verify this requirement with your plan.

Once diagnosed, SHP generally covers ongoing medication management visits at standard specialist copay rates. Most plans allow 90-day prescription fills for maintenance stimulant therapy after an initial 30-day trial period, which can reduce per-unit costs and pharmacy visit frequency.

Cost-Saving Strategies for SHP Members

Even with insurance coverage, stimulant medications can carry meaningful out-of-pocket costs. Several strategies can reduce your expenses within the SHP framework.

Mail-order pharmacy benefits through SHP's PBM often provide 90-day supplies at the cost of two copays rather than three. For a Tier 2 generic with a $15 copay, this saves $15 every three months ($60 per year). SHP members in Marshfield Clinic's integrated system may also access in-house pharmacies with negotiated pricing.

Manufacturer copay cards exist for some brand-name ADHD medications but not for Schedule II controlled substances like Adderall. The FDA's controlled substance regulations and DEA scheduling rules limit promotional discount programs for stimulants [8]. However, authorized generic programs from Teva and Sandoz sometimes offer limited patient assistance for uninsured or underinsured patients.

If SHP denies coverage for your prescribed formulation, consider these alternatives. Ask your prescriber about therapeutically equivalent options that sit on a lower formulary tier. For example, if Adderall XR is denied, generic dextroamphetamine ER (the single-isomer version) might be covered at a lower tier. Lisdexfetamine (Vyvanse), while typically more expensive, became available as a generic in 2023 and some SHP plans may now cover it at a preferred tier.

The GoodRx and RxSaver platforms show retail cash prices at nearby pharmacies, which occasionally beat insurance copays for low-dose generic stimulants. A 30-day supply of generic mixed amphetamine salts 20 mg IR can cost as little as $25 to $35 cash at certain pharmacies [9].

Comparing SHP Stimulant Coverage to Wisconsin Market Norms

SHP operates primarily in Wisconsin, where it competes with major carriers including Quartz (formerly Physicians Plus), Dean Health Plan, Group Health Cooperative, and UnitedHealthcare. Its stimulant coverage policies are broadly consistent with Wisconsin market norms, but a few differences are worth noting.

SHP's integration with Marshfield Clinic means that in-network prescribers can access the formulary and PA status directly through the Epic electronic health record, reducing delays in PA processing. Members who see Marshfield Clinic providers often experience faster PA turnaround (sometimes same-day) compared to out-of-network prescribers submitting by fax. This operational advantage is measurable. A 2021 JAMA Network Open study found that integrated health system PA workflows reduced medication access delays by 2.4 days on average compared to non-integrated systems [10].

According to a CDC National Health Statistics Report, stimulant prescription rates vary by region, with the Midwest averaging 5.1% of adults aged 20 to 64 filling at least one stimulant prescription annually [11]. Wisconsin falls near this regional average. SHP's formulary reflects this utilization pattern by maintaining broad generic stimulant access while applying utilization controls to limit misuse.

For SHP Medicare Advantage members specifically, Part D regulations apply. CMS excluded most benzodiazepines and barbiturates from Part D coverage until 2013 but has always included ADHD stimulants. SHP's Medicare Advantage Part D formulary covers generic amphetamine mixed salts with standard utilization management, consistent with CMS formulary guidelines.

What to Do If SHP Denies Your Adderall Prescription

A coverage denial is not the end of the road. SHP provides a structured appeals process that members should understand before they need it.

First, determine the reason for denial. Common reasons include missing PA, step-therapy requirements not met, quantity limit exceeded, or non-formulary status. Your explanation of benefits (EOB) document will specify the denial reason and cite the relevant plan provision.

For PA-related denials, your prescriber submits a PA request with supporting clinical documentation. SHP's PA criteria for stimulants typically require confirmation of ADHD diagnosis, documentation of functional impairment, and a medication history showing which agents have been tried. If the standard PA is denied, the first appeal goes to SHP's pharmacy and therapeutics (P&T) committee. The AMA's prior authorization reform principles recommend that insurers complete PA reviews within 48 hours, and SHP generally meets this benchmark for urgent requests [12].

Second-level appeals for commercial plans may involve an independent external review organization (IRO), as required by the Affordable Care Act's external review provisions. Wisconsin's Office of the Commissioner of Insurance (OCI) oversees external reviews for state-regulated plans. The external reviewer evaluates whether the denial was consistent with evidence-based clinical guidelines.

For Medicare Advantage members, the appeals process follows CMS's five-level structure: plan reconsideration, independent review entity (IRE), Administrative Law Judge, Medicare Appeals Council, and federal court. Most stimulant coverage disputes are resolved at the first or second level.

Document everything. Keep copies of your prescriber's PA submissions, denial letters, and appeal correspondence. If your prescriber supports the medical necessity of a specific formulation, their detailed letter is the single most important piece of your appeal.

SHP Behavioral Health and ADHD Program Benefits

Beyond medication coverage, SHP offers behavioral health services relevant to ADHD management. Cognitive behavioral therapy (CBT) adapted for ADHD has a growing evidence base as an adjunct to pharmacotherapy.

A randomized controlled trial published in JAMA Psychiatry (N=86) demonstrated that CBT combined with medication produced significantly greater symptom reduction than medication alone in adults with ADHD, with benefits persisting at 12-month follow-up [13]. SHP covers individual therapy sessions with in-network behavioral health providers, typically at a specialist copay of $20 to $50 per visit after any applicable deductible.

SHP also covers neuropsychological testing when ordered by an in-network provider for diagnostic clarification. Comprehensive ADHD evaluations, which may include 4 to 8 hours of testing across multiple sessions, are covered under the behavioral health benefit with standard cost-sharing. Some SHP plans require preauthorization for neuropsychological testing exceeding three sessions.

The American Psychiatric Association practice guidelines recommend multimodal treatment for adult ADHD, combining pharmacotherapy with psychoeducation and, when available, ADHD-specific CBT [14]. SHP's coverage structure supports this approach by covering both medication and therapy within the same benefit plan.